Genzyme's John Butler sparks Inspiration as CEO
This article was originally published in Scrip
Executive Summary
Inspiration Biopharmaceuticals, a biopharmaceutical company focused on finding new treatments for haemophilia, has appointed John Butler CEO, replacing Dr Michael Griffith, who has taken the role of chief scientific officer and retains the title of president. Mr Butler joins Inspiration from Genzyme Corporation, where he most recently served as president of the company's rare genetic diseases business.